RemeGen Co., Ltd. (HKG:9995)
Hong Kong · Delayed Price · Currency is HKD 84.30
-0.15 (-0.18%)
Nov 20, 2025, 9:29 AM HKT
RemeGen Revenue
RemeGen had revenue of 621.88M CNY in the quarter ending September 30, 2025, with 33.13% growth. This brings the company's revenue in the last twelve months to 2.23B, up 46.34% year-over-year. In the year 2024, RemeGen had annual revenue of 1.72B with 58.54% growth.
Revenue (ttm)
2.23B CNY
Revenue Growth
+46.34%
P/S Ratio
20.97
Revenue / Employee
742.85K CNY
Employees
2,999
Market Cap
51.05B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.89B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |